Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms

INTRODUCTION: The phase 3 CLEAR study demonstrated that lenvatinib plus pembrolizumab significantly improved efficacy versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma (RCC). Prognostic features including presence and/or site of baseline metastases, prior nephr...

Descripción completa

Detalles Bibliográficos
Autores principales: Grünwald, Viktor, Powles, Thomas, Eto, Masatoshi, Kopyltsov, Evgeny, Rha, Sun Young, Porta, Camillo, Motzer, Robert, Hutson, Thomas E., Méndez-Vidal, María José, Hong, Sung-Hoo, Winquist, Eric, Goh, Jeffrey C., Maroto, Pablo, Buchler, Tomas, Takagi, Toshio, Burgents, Joseph E., Perini, Rodolfo, He, Cixin, Okpara, Chinyere E., McKenzie, Jodi, Choueiri, Toni K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10471185/
https://www.ncbi.nlm.nih.gov/pubmed/37664025
http://dx.doi.org/10.3389/fonc.2023.1223282

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10471185/
https://www.ncbi.nlm.nih.gov/pubmed/37664025
http://dx.doi.org/10.3389/fonc.2023.1223282

Ejemplares similares